% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Vogel:302997,
      author       = {J. Vogel and P. Luedike and K. Hellhammer and S.
                      Settelmeier and S. Jura and F. Buehning and T. Lerchner and
                      T. Mondritzki and A. Carpinteiro and A. Reinhardt$^*$ and F.
                      Schindhelm and A. A. Mahabadi and T. Rassaf and L. Michel},
      title        = {{S}afety and {F}easibility of {T}ranscatheter
                      {E}dge-to-{E}dge {R}epair of {M}itral {R}egurgitation in
                      {C}ardiac {A}myloidosis.},
      journal      = {JACC: advances},
      volume       = {4},
      number       = {8},
      issn         = {2772-963X},
      address      = {[Amsterdam]},
      publisher    = {Elsevier B.V.},
      reportid     = {DKFZ-2025-01444},
      pages        = {101998},
      year         = {2025},
      abstract     = {Cardiac amyloidosis (CA) is characterized by amyloid
                      deposits in the heart leading to various manifestations
                      including heart failure (HF). CA patients often present with
                      severe mitral regurgitation (MR), complicating management in
                      patients. Transcatheter edge-to-edge repair (TEER) offers an
                      interventional option for patients at high surgical risk.The
                      objective of this study was to assess the safety, efficacy,
                      and clinical outcomes of TEER in patients with CA and severe
                      MR.This retrospective study included 27 patients with CA and
                      81 matched patients with HF without CA and severe MR who
                      underwent TEER. Outcome parameters included technical
                      success, echocardiographic response, laboratory biomarkers,
                      and clinical symptom burden. Follow-up was performed at a
                      median of 103 days (90-144) and included clinical
                      assessment, echocardiography, and laboratory
                      analysis.Patients had a median age of 79 (75-83) years with
                      $86.1\%$ male and NYHA functional class ≥III in $85.1\%$
                      prior to intervention. TEER was successful in $100\%$ in
                      both groups. Symptom burden improved in both groups (NYHA
                      functional class I/II in $50.5\%$ vs $57.8\%,$ CA vs HF). MR
                      was reduced, achieving MR ≤2+ in $100\%,$ with a reduction
                      in regurgitant volume in both groups (P < 0.001). No
                      procedure-related major adverse events were reported with a
                      $100\%$ 30-day survival rate. Scoring for MR anatomical
                      complexity did not show a difference.The study demonstrated
                      safety and feasibility of TEER in patients with CA and
                      severe MR, with satisfactory procedure-related outcome and
                      absence of severe adverse events, thus highlighting the
                      potential benefits in CA patients.},
      keywords     = {HFpEF (Other) / cardiac amyloidosis (Other) /
                      cardiomyopathy (Other) / edge-to-edge-repair (Other) / heart
                      failure (Other) / mitral regurgitation (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40675021},
      doi          = {10.1016/j.jacadv.2025.101998},
      url          = {https://inrepo02.dkfz.de/record/302997},
}